R&D jobs facing the axe at Glaxo

GlaxoSmithKline today outlined plans to slash 850 research and development jobs with workers in London in the firing line.

The drugs giant, which has 15,000 R&D staff including 5000 at four sites in London and Hertfordshire, said the jobs will go in the UK and US.

It follows a review by former chief executive Jean-Pierre Garnier who outlined plans to save £700 million by 2010, which has been continued by his successor Andrew Witty, as the pharmaceutical industry faces the challenge of cheap copycat drugs, demands for more cost-effective healthcare, and the need for new and better medicines.

"Following a recent review of business operations we have started consultation on proposals which could impact 850 roles with R&D in the UK and US," a spokeswoman said.

"We believe these changes are necessary as part of GSK's longer-term strategy.

"Regrettably some job reductions are necessary and we will do everything we can to support those employees who are affected."